Biomay Expands DNA Manufacturing Portfolio with Cell-free Enzymatic DNA Synthesis
(October 26, 2026) New technology complements Biomay’s established plasmid DNA manufacturing capabilities. As the result of focused internal research and development, the company has filed a patent application earlier this year. Biomay is now implementing the technology for GMP manufacturing, with the first GMP batches completed by end of this year.
> More infoBiomay Launches Fast-track Manufacturing for Personalized mRNA and DNA Cancer Vaccines
(October 21, 2026) Biomay highlights its dedicated manufacturing platform for neoantigen-based cancer vaccines. Designed for the demanding timelines of individualized cancer immunotherapies, it enables the production of personalized DNA cancer vaccines in as little as two weeks and mRNA-based vaccines in approximately three weeks from starting material to release.
> More info